Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 6:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: clinical course Clear all
Recruiting No phase listed Observational

Clinical Course Of Disease In Participants With FA-CM

NCT06865482
View directory record Official record
Conditions
Friedreich Ataxia, Cardiomyopathy
Interventions
Not listed
Lead sponsor
Lexeo Therapeutics
Industry
Eligibility
6 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
8
States / cities
La Jolla, California • Tampa, Florida • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 22, 2026, 6:55 PM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Antibiotic Treatment and Long-term Outcomes of Patients With Pseudomyxoma Peritonei of Appendiceal Origin

NCT02387203
View directory record Official record
Conditions
Pseudomyxoma Peritonei, Appendiceal Neoplasms
Interventions
PrevPac (Prevacid, Amoxicillin, Clarithromycin)
Drug
Lead sponsor
Mercy Medical Center
Other
Eligibility
21 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 18, 2024 · Synced Sep 22, 2026, 6:55 PM EDT
Recruiting Not applicable Interventional

A Pilot of a Microdevice For In Situ Candidate Drug Screening in Cutaneous Lesions of T-Cell Lymphoma

NCT04045470
View directory record Official record
Conditions
Cutaneous T Cell Lymphoma, Peripheral T Cell Lymphoma
Interventions
Microdevices, Standard of care therapy, Standard of care systemic therapy
Device · Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 26, 2026 · Synced Sep 22, 2026, 6:55 PM EDT
Not listed Phase 2 Interventional

Simvastatin to Prevent SCI-Induced Bone Loss

NCT02946424
View directory record Official record
Conditions
Spinal Cord Injuries, Osteoporosis
Interventions
Placebo Oral Capsule, Simvastatin
Drug
Lead sponsor
Craig Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Englewood, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 7, 2021 · Synced Sep 22, 2026, 6:55 PM EDT
Completed Not applicable Interventional

Emotion Regulation Therapy for Clinical Worry and Rumination

NCT04060940
View directory record Official record
Conditions
Anxiety Disorders and Symptoms, Depression, Anxiety, Generalized Anxiety Disorder, Emotional Dysfunction
Interventions
Emotion Regulation Therapy: 8-session version, Emotion Regulation Therapy: 16-session version
Behavioral
Lead sponsor
Douglas Mennin
Other
Eligibility
18 Years to 29 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 16, 2022 · Synced Sep 22, 2026, 6:55 PM EDT
Completed Phase 1 Interventional

Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma

NCT02332850
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Isatuximab, Carfilzomib, Dexamethasone
Biological · Drug
Lead sponsor
Thomas Martin, MD
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
5
States / cities
San Francisco, California • Denver, Colorado • Hackensack, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 22, 2026, 6:55 PM EDT
Completed Phase 2 Interventional Results available

Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women)

NCT00499083
View directory record Official record
Conditions
Breast Cancer
Interventions
therapeutic autologous dendritic cells, aromatase inhibition therapy, cyclophosphamide, doxorubicin hydrochloride, paclitaxel, tamoxifen citrate, gene expression analysis, protein expression analysis, reverse transcriptase-polymerase chain reaction, immunoenzyme technique, immunohistochemistry staining method, laboratory biomarker analysis, adjuvant therapy, biopsy, conventional surgery, neoadjuvant therapy, radiation therapy
Biological · Drug · Genetic + 3 more
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 120 Years · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
2
States / cities
Tampa, Florida • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Sep 22, 2026, 6:55 PM EDT
Completed Phase 2 Interventional Results available

Bevacizumab and Low-Dose Cyclophosphamide in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer

NCT00072566
View directory record Official record
Conditions
Primary Peritoneal Carcinoma, Recurrent Ovarian Carcinoma, Stage IV Ovarian Cancer
Interventions
Bevacizumab, Cyclophosphamide, Laboratory Biomarker Analysis
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated May 11, 2015 · Synced Sep 22, 2026, 6:55 PM EDT
Completed Not applicable Interventional Results available

CBTpro: Scaling up CBT for Psychosis Using Simulated Patients and Spoken Language Technologies

NCT05127837
View directory record Official record
Conditions
Psychosis, Schizophrenia, Schizo Affective Disorder, Bipolar Disorder, Depressive Disorder
Interventions
CBTpro
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 100 Years
Enrollment
601 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
13
States / cities
Los Angeles, California • Morgan Hill, California • San Jose, California + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 22, 2026, 6:55 PM EDT
Completed Early Phase 1 Interventional

Neuropharmacokinetics of Eribulin Mesylate in Treating Patients With Primary or Metastatic Brain Tumors

NCT02338037
View directory record Official record
Conditions
Metastatic Malignant Neoplasm in the Adult Brain, Primary Brain Tumor
Interventions
Therapeutic Conventional Surgery, Biopsy, Eribulin Mesylate, Microdialysis, Pharmacological Study
Procedure · Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Sep 22, 2026, 6:55 PM EDT
Recruiting Not applicable Interventional

Engaging Mental Health Services for Preschoolers at Risk

NCT07054554
View directory record Official record
Conditions
Mental Health Disorder, Family Navigation, Minoritized Population, Preschool Age Children
Interventions
NTRI-MH
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Sep 22, 2026, 6:55 PM EDT
Recruiting Not applicable Interventional

Adaptive Neurostimulation to Restore Sleep in Parkinson's Disease (Aim 2)

NCT05070013
View directory record Official record
Conditions
Parkinson's Disease, Sleep Fragmentation
Interventions
Deep Brain Stimulation
Device
Lead sponsor
University of Nebraska
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Omaha, Nebraska • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 21, 2025 · Synced Sep 22, 2026, 6:55 PM EDT
Completed Not applicable Interventional Results available

Clinical Evaluation of a Silicone Hydrogel Daily Wear Monthly Replacement Contact Lens

NCT04422990
View directory record Official record
Conditions
Refractive Errors
Interventions
Lehfilcon A contact lenses, Comfilcon A contact lenses, CLEAR CARE
Device
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
14
States / cities
Los Angeles, California • Novato, California • Oakland, California + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Sep 22, 2026, 6:55 PM EDT
Active, not recruiting Phase 4 Interventional

HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors

NCT02875314
View directory record Official record
Conditions
Medulloblastoma, Central Nervous System Embryonal Tumors
Interventions
Induction, Single Cycle Intensive Chemotherapy, Tandem 3 Cycle Intensive Chemotherapy
Drug
Lead sponsor
Parth Patel
Other
Eligibility
Up to 10 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2030
U.S. locations
55
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 47 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 22, 2026, 6:55 PM EDT
Not listed Phase 1 Interventional

IL-2 Plus Abatacept in FTD

NCT06395038
View directory record Official record
Conditions
Frontotemporal Degeneration
Interventions
Abatacept plus Aldesleukin
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years to 86 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 9, 2025 · Synced Sep 22, 2026, 6:55 PM EDT
Terminated Phase 1 Interventional

RO4929097 and Vismodegib in Treating Patients With Breast Cancer That is Metastatic or Cannot Be Removed By Surgery

NCT01071564
View directory record Official record
Conditions
Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma
Interventions
Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Pharmacogenomic Study, Pharmacological Study, Vismodegib
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
3
States / cities
Baltimore, Maryland • Ann Arbor, Michigan • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Sep 22, 2026, 6:55 PM EDT
Completed Phase 2 Interventional Results available

HIF-2 Alpha Inhibitor PT2385 in Treating Patients With Recurrent Glioblastoma

NCT03216499
View directory record Official record
Conditions
Recurrent Glioblastoma
Interventions
HIF-2alpha Inhibitor PT2385, Pharmacological Study, Laboratory Biomarker Analysis, Pharmacogenomic Study
Drug · Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated May 8, 2022 · Synced Sep 22, 2026, 6:55 PM EDT
Recruiting Not applicable Interventional

Accelerated TMS for Freezing of Gait in Parkinson's Disease

NCT06982638
View directory record Official record
Conditions
Parkinson&#39;s Disease (PD)
Interventions
TMS+ Gait training
Device
Lead sponsor
Medical University of South Carolina
Other
Eligibility
50 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 22, 2026, 6:55 PM EDT
Recruiting Phase 2 Interventional

Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid Leukemia

NCT03737955
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Gemtuzumab Ozogamicin, Quality-of-Life Assessment, Bone Marrow Aspiration, Biospecimen Collection
Drug · Other · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 22, 2026, 6:55 PM EDT
Terminated Phase 1 Interventional Results available

Trial of Topical Verapamil in Chronic Rhinosinusitis With Nasal Polyps

NCT03102190
View directory record Official record
Conditions
Sinusitis, Nasal Polyps
Interventions
Verapamil Hydrochloride Intranasal
Drug
Lead sponsor
Benjamin Bleier
Other
Eligibility
18 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced Sep 22, 2026, 6:55 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Ginger in Treating Nausea in Patients Receiving Chemotherapy for Cancer

NCT00040742
View directory record Official record
Conditions
Nausea, Vomiting
Interventions
ginger, placebo
Dietary Supplement · Other
Lead sponsor
Gary Morrow
Other
Eligibility
18 Years to 120 Years
Enrollment
745 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
19
States / cities
Mobile, Alabama • Honolulu, Hawaii • Chicago, Illinois + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2015 · Synced Sep 22, 2026, 6:55 PM EDT
Completed Not applicable Interventional

Suprapatellar Versus Infrapatellar Nailing in Tibial Fractures: A Pilot Study

NCT01341418
View directory record Official record
Conditions
Tibial Fractures
Interventions
Suprapatellar approach, Infrapatellar approach
Procedure
Lead sponsor
Florida Orthopaedic Institute
Network
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 13, 2017 · Synced Sep 22, 2026, 6:55 PM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Disorders of the Acute Phase Response Following Trauma and Invasive Surgery

NCT03741023
View directory record Official record
Conditions
Acute Phase Response
Interventions
Blood draw (venipuncture or fingerstick)
Procedure
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
2 Months and older
Enrollment
320 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 22, 2026, 6:55 PM EDT
Completed Not applicable Interventional Results available

Probiotics to Prevent Relapse After Hospitalization for Mania

NCT01731171
View directory record Official record
Conditions
Bipolar Disorder, Schizoaffective Disorder
Interventions
Probiotic Supplement, Inert Compound
Dietary Supplement
Lead sponsor
Sheppard Pratt Health System
Other
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 6, 2019 · Synced Sep 22, 2026, 6:55 PM EDT